Welcome to our dedicated page for ENDRA Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on ENDRA Life Sciences stock.
ENDRA Life Sciences Inc. (symbol: NDRA), is revolutionizing the field of ultrasound with its groundbreaking photo-acoustic solutions. The company’s innovations enable medical researchers to screen and modify disease models with unmatched quality and speed. ENDRA Life Sciences has established a global installed base of top-tier institutions utilizing their Nexus-128 system, the only comprehensive 3D imaging solution designed for imaging anatomy, physiology, and labeled molecular targets.
The Nexus 128 is a sophisticated preclinical photoacoustic computed tomography (CT) scanner tailored for small animal imaging. It facilitates quick, non-invasive quantification of physiological parameters, such as tumor vasculature, without the need for ionizing radiation. The fully 3D imaging technology of the Nexus 128 enhances sensitivity compared to traditional slice-based scanners, and its dynamic (4D) photoacoustic CT scans support advanced applications like quantification of probe uptake. Currently, leading imaging laboratories worldwide leverage the Nexus 128 for various research purposes.
Additionally, ENDRA Life Sciences is developing Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which aims to visualize tissue with MRI-like clarity but at a fraction of the cost and at the point of patient care. The TAEUS technology is designed to integrate with approximately 400,000 cart-based ultrasound systems in use globally. Initially, TAEUS focuses on measuring liver fat to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions affecting over a billion people worldwide, for which there are currently no effective diagnostic tools. Beyond liver applications, TAEUS is also being explored for several other clinical uses, such as visualizing tissue temperature during energy-based surgical procedures.
ENDRA Life Sciences continues to push the boundaries of medical imaging technology, collaborating with various partners to further enhance their solutions. Stay updated with the latest achievements, projects, and news from ENDRA Life Sciences to understand their impact and progression in the medical technology landscape.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has announced its plans to report financial results for Q2 2024 on August 14, 2024, after the U.S. financial markets close. The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results, provide updates on recent corporate developments, and answer questions.
Participants are encouraged to pre-register for the call using a provided link, which will grant them immediate access with a unique PIN. Those unable to pre-register can dial in using specific U.S. and International numbers. A webcast of the call will be accessible through ENDRA's Investor Relations page. Both telephone and webcast replays will be available until August 21, 2024.
ENDRA Life Sciences (Nasdaq: NDRA) announced the pricing of an $8.0 million public offering. The offering includes 61,538,461 shares of common stock or pre-funded warrants, each paired with Series A and B Warrants. The Series A Warrants have an exercise price of $0.22 per share, while Series B Warrants offer an alternative cashless exercise option. The closing date is expected around June 5, 2024, pending customary conditions. Net proceeds will be used for working capital and general corporate purposes. Craig-Hallum is the sole placement agent. This offering follows an SEC-approved registration statement on Form S-1.
ENDRA Life Sciences (NASDAQ: NDRA), a pioneer in Thermo Acoustic Enhanced UltraSound (TAEUS®), announced a significant update following an in-person meeting with the FDA. The meeting focused on the clinical trial design of the TAEUS liver device, which is important for ENDRA's U.S. De Novo filing. ENDRA presented a detailed description of TAEUS technology and a synopsis of their clinical study, which spans a fat fraction range representative of steatotic liver disease in the U.S.
The company provided background clinical data and statistical analyses from 45 historical study participants. The meeting highlighted ENDRA's proposed pivotal clinical study and included a demonstration of the TAEUS procedure. Key ENDRA team members, including technical staff and biostatisticians, attended the meeting. The FDA's feedback was deemed constructive, and ENDRA plans to update its clinical study protocol and statistical plan for FDA submission. This close engagement aims to ensure alignment on the pivotal study design for a future De Novo submission.
ENDRA Life Sciences (NASDAQ: NDRA) announced its Q1 2024 financial results, reporting a net loss of $2.8 million, or $0.26 per share, a slight improvement from a $2.9 million net loss in Q1 2023. Operating expenses decreased to $2.8 million from $2.9 million due to lower R&D costs. Cash and cash equivalents stood at $1.1 million as of March 31, 2024.
Key developments include the installation of the first TAEUS system in the UK at King’s College Hospital for clinical evaluation, aimed at assessing its liver fat measurement accuracy against MRI. The study will involve approximately 75 subjects. ENDRA is also advancing its FDA De Novo application for TAEUS, with a pre-submission meeting scheduled for Q2 2024. The company expanded its intellectual property portfolio, obtaining eight new patents in Europe and China, bringing the total to 80 issued patents globally. ENDRA is exploring licensing opportunities in non-core indications to enhance its IP portfolio value.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will report financial results for the first quarter of 2024 on May 14, 2024. The company will hold a conference call and webcast to discuss the results and recent corporate developments. Participants can pre-register for the call for immediate access.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has strengthened its intellectual property with the issuance of five new international patents, including three in Europe and two in China. This brings ENDRA's IP portfolio to a milestone of 80 issued patents worldwide, protecting its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. The patents cover innovative solutions for providing RF energy to tissue, determining material types, and monitoring tissue temperature during surgical procedures, expanding the application of TAEUS technology.
FAQ
What is the current stock price of ENDRA Life Sciences (NDRA)?
What is the market cap of ENDRA Life Sciences (NDRA)?
What does ENDRA Life Sciences Inc. specialize in?
What is the Nexus-128 system?
What are the applications of the TAEUS technology?
Who uses the Nexus-128 system?
How does the Nexus-128 system benefit medical research?
What are NAFLD and NASH?
How is TAEUS technology integrated into existing ultrasound systems?
What makes ENDRA's imaging technology unique?
Are there other clinical applications for TAEUS technology?
Where can I find the latest news and updates about ENDRA Life Sciences?
